Haemonetics Akcija

Haemonetics EBITDA

Vrijednost EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Haemonetics (HAE) na dan 19. авг 2026. je 241,40 М USD. Prethodne godine, EBITDA (Заработак пре камата, пореза, амортизације и отписивања) je bio 270,08 М USD — promjena od -10,62% (niži).

EBITDA

241,40 МUSD

YoY

-10,62%

Zadnja ažuriranja:

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Haemonetics je 2026 241,40 М USD. EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Haemonetics je bio 2025 270,08 М USD. Pad je time -10,62% niži u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

Haemonetics Анализа акција

Šta radi Haemonetics? Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji Haemonetics

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) kompanije Haemonetics iznosi 241,40 М USD u 2026. godini.

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Haemonetics se promijenio sa 270,08 М USD na 241,40 М USD, što predstavlja promjenu od -10,62%. Vrijednost je niži nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EBITDA (Заработак пре камата, пореза, амортизације и отписивања) Haemonetics od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

EBITDA мери оперативну перформансу пре утицаја финансијске структуре, окружења пореза и не-готовинских отписивања.

EBITDA = EBIT + Амортизација и отписивање

EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s USD je ključan faktor za investitore. Promene u ovoj metrici mogu signalizirati poboljšane ili pogoršane fundamentalne faktore, direktno utiču na cenu akcije. Na Eulopoolu, možete pratiti EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s Haemonetics istorijski i u realnom vremenu.

Access this data via the Eulerpool API

Извештај о добити и губитку — Haemonetics

Sve ključne metrike — Haemonetics

Раст